Overview

Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma

Status:
Recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

We hypothesized that intra-arterial gemcitabine/oxaliplatin administered as second-line treatment could strongly improve objective response rate at 4 months after inclusion in patient with non-metastatic unresectable intra-hepatic cholangiocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital, Montpellier

Collaborator:

Federation Francophone de Cancerologie Digestive

Treatments:

Gemcitabine
Oxaliplatin